Academic Detailing for HIV Prevention

(ADOPT-PrEP Trial)

Overseen By Carly Guss, MD, MPH

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Boston Children's Hospital

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

50 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether participants must stop taking their current medications.

What data supports the effectiveness of the treatment Academic detailing for HIV prevention?

The study on improving adherence to care among 'hard to reach' HIV-infected patients in Argentina suggests that training healthcare providers in specific communication techniques can improve patient adherence to treatment and viral suppression, which is similar to the goals of academic detailing. ^{1 2 3 4 5}

How does the treatment Academic Detailing for HIV Prevention differ from other treatments for HIV prevention?

Academic detailing is unique because it focuses on providing personalized education and support to healthcare providers to improve their knowledge and practices related to HIV prevention. Unlike traditional treatments that directly target the virus or its transmission, this approach aims to enhance the implementation of existing prevention strategies by ensuring that healthcare providers are well-informed and equipped to deliver effective interventions. ^{6 7 8 9 10}

What is the purpose of this trial?

In this study, 50 pediatricians will participate in academic detailing, an evidence-based, 1-on-1 outreach education technique intended to promote clinician behavior change through brief, highly interactive, and individualized dialogues with trained educators, or "detailers". The goals of this study are to learn about whether this is a practical and acceptable technique, and whether it changes how pediatricians prescribe pre-exposure prophylaxis (PrEP) to adolescents and young adults (AYA) and how patients take it.

Eligibility Criteria

This trial is for primary care providers at Boston Children's Hospital Adolescent/Young Adult Medicine, Martha Eliot Health Center, or Children's Hospital Primary Care Center. There are no specific exclusion criteria mentioned.

Inclusion Criteria

Primary care provider at one of our 3 study sites (Boston Children's Hospital Adolescent/Young Adult Medicine, Martha Eliot Health Center, Children's Hospital Primary Care Center)

Exclusion Criteria

Not applicable.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Academic Detailing Intervention

Pediatric providers participate in academic detailing sessions to improve PrEP prescribing practices

1 month

2 academic detailing visits

Follow-up

Participants are monitored for changes in PrEP prescriptions, persistence, and HIV testing

6 months

Treatment Details

Interventions

• Academic detailing

Trial Overview The study tests academic detailing as a method to improve how pediatricians prescribe PrEP (a medication to prevent HIV) to adolescents and young adults. It involves personalized education sessions with trained educators aiming to change clinician behavior.

Participant Groups

Group I: pediatricians Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Boston Children's Hospital

Lead Sponsor

Trials

801

Recruited

5,584,000+

Findings from Research

Effective HIV prevention today requires a combination of behavioral, biomedical, and structural strategies, including consistent condom use, reducing the number of sexual and needle-sharing partners, male circumcision, and antiretroviral treatment.

Despite the identification of 144 effective behavioral prevention programs, scaling these initiatives outside the United States has been limited, highlighting the need for integrating behavioral strategies with biomedical innovations to enhance overall effectiveness in HIV prevention.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Rotheram-Borus, MJ., Swendeman, D., Chovnick, G.[2022]

References

1. England pubmed.ncbi.nlm.nih.gov

The Link4Health study to evaluate the effectiveness of a combination intervention strategy for linkage to and retention in HIV care in Swaziland: protocol for a cluster randomized trial. [2022]

2. United States pubmed.ncbi.nlm.nih.gov

HIV laboratory monitoring reliably identifies persons engaged in care. [2020]

3. United States pubmed.ncbi.nlm.nih.gov

Improving Adherence to Care Among "Hard to Reach" HIV-Infected Patients in Argentina. [2018]

4. United States pubmed.ncbi.nlm.nih.gov

Clinical decision tools are needed to identify HIV-positive patients at high risk for poor outcomes after initiation of antiretroviral therapy. [2018]

5. United States pubmed.ncbi.nlm.nih.gov

Decreasing Missed Opportunities for HIV Testing in Primary Care through Enhanced Utilization of the Electronic Medical Record. [2021]

6. United States pubmed.ncbi.nlm.nih.gov

The future of HIV prevention. [2020]

7. United States pubmed.ncbi.nlm.nih.gov

Bridging the gap between science and practice: insight to researchers from practitioners. [2018]

8. United States pubmed.ncbi.nlm.nih.gov

Behavioral and social science research to support accelerated and equitable implementation of long-acting preexposure prophylaxis. [2022]

9. United States pubmed.ncbi.nlm.nih.gov

The use of epidemiologic and other data in selecting behavioral HIV prevention interventions for African American women. [2022]

10. United States pubmed.ncbi.nlm.nih.gov

The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. [2022]